Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations - Wikidata - awgldk - TriplyDB

Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations

Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations

http://www.wikidata.org/entity/Q36703641

about

BRCA2 and homologous recombination BRCA2 is ubiquitinated in vivo and interacts with USP11, a deubiquitinating enzyme that exhibits prosurvival function in the cellular response to DNA damage Highlight: BRCA1 and BRCA2 proteins in breast cancer Deficiency of human BRCA2 leads to impaired homologous recombination but maintains normal nonhomologous end joining The Icelandic founder mutation BRCA2 999del5: analysis of expression Molding BRCA2 function through its interacting partners Analysis of murine Brca2 reveals conservation of protein-protein interactions but differences in nuclear localization signals Inhibition of breast and brain cancer cell growth by BCCIPalpha, an evolutionarily conserved nuclear protein that interacts with BRCA2 Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer Suppression of the DNA repair defects of BRCA2-deficient cells with heterologous protein fusions.Cellular redistribution of Rad51 in response to DNA damage: novel role for Rad51C.Comprehensive genomic analysis of a BRCA2 deficient human pancreatic cancer Variation in cancer risks, by mutation position, in BRCA2 mutation carriers.Mutation in Brca2 stimulates error-prone homology-directed repair of DNA double-strand breaks occurring between repeated sequences.Interaction with BRCA2 suggests a role for filamin-1 (hsFLNa) in DNA damage response.Plasticity of BRCA2 function in homologous recombination: genetic interactions of the PALB2 and DNA binding domains.Functional assays for classification of BRCA2 variants of uncertain significance.BRCA2 and Smad3 synergize in regulation of gene transcription.Brca2 (XRCC11) deficiency results in radioresistant DNA synthesis and a higher frequency of spontaneous deletions Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers.Two classes of BRC repeats in BRCA2 promote RAD51 nucleoprotein filament function by distinct mechanisms.Chromosomal instability and cancer predisposition: insights from studies on the breast cancer susceptibility gene, BRCA2.BRCA2 cooperates with histone acetyltransferases in androgen receptor-mediated transcription.Brca2 deficiency leads to T cell loss and immune dysfunction.Functional assays for BRCA1 and BRCA2.The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability.Spectrum and characterisation of BRCA1 and BRCA2 deleterious mutations in high-risk Czech patients with breast and/or ovarian cancer.Novel patient-derived xenograft mouse model for pancreatic acinar cell carcinoma demonstrates single agent activity of oxaliplatin.Restoration of CAPAN-1 cells with functional BRCA2 provides insight into the DNA repair activity of individuals who are heterozygous for BRCA2 mutations.Effect of the novel Moroccan BRCA1 and BRCA2 frameshift mutations.A cancer-associated BRCA2 mutation reveals masked nuclear export signals controlling localization Degradation of BRCA2 in alkyltransferase-mediated DNA repair and its clinical implications Familial breast/ovarian cancer and BRCA1/2 genetic screening: the role of immunohistochemistry as an additional method in the selection of patients Functional assays for analysis of variants of uncertain significance in BRCA2.BRCA2: one small step for DNA repair, one giant protein purified.Prolonged exposure to particulate chromate inhibits RAD51 nuclear import mediator proteins.Cyclin D1 promotes BRCA2-Rad51 interaction by restricting cyclin A/B-dependent BRCA2 phosphorylation.Distinct binding of BRCA2 BRC repeats to RAD51 generates differential DNA damage sensitivity.Genome annotation by shotgun inactivation of a native gene in hemizygous cells: application to BRCA2 with implication of hypomorphic variants.

P2860

Q24291786-F1DB9D7D-BCF1-48D4-91DF-A8F5FE5B48D9 Q24301487-ED6CF422-9054-4F42-A53E-9303F0121189 Q24307401-F359CFC6-07D2-4DE0-9F4B-F831A458D926 Q24630418-DA6ADE9F-8060-4B8A-8ADE-62799428B92D Q24805817-45725E33-BF4C-43E6-AFD0-18BB5195B584 Q28085603-9A3FBE10-3949-47C2-96F1-2E5F39CFA0D8 Q28209536-3BE2F04C-866D-4319-97EB-0360D3E7D73A Q28213827-00BCA0B9-E950-4F84-A5F7-ED0E0937AF11 Q28943461-9A1D945E-23A2-498A-A380-B3E4DC5A19C6 Q33244989-78863317-E326-45C5-9798-7FEE08CF8E8E Q33553786-B837E9AF-F199-4442-80BB-313215423816 Q33959327-59A30663-D352-42F4-A66F-525A6F77A824 Q34044197-778BCEEC-5EBA-4F28-91A4-59805133B93D Q34081887-ED543764-7852-431D-AFD0-71382787B863 Q34095307-17B1AED9-587B-46EC-A023-8474AB3A6B9A Q34109816-405531DA-8C1E-497F-8399-CDA8AD9BF83F Q34116524-7233A904-A793-40EC-8499-D3499A6F52AC Q34143239-651A46CB-A508-4E25-9C3F-8DBC77A05F09 Q34440261-8B325999-9C37-4396-BE68-54C693F04B2F Q34992260-EFA0204B-69B3-447E-8EE6-8EBBB25EA724 Q35018746-B58A4B5C-5B04-4FEC-8E64-1E8FCE254408 Q35081603-43377137-6855-404E-9CB0-CECABB738D78 Q35132670-80E7A519-9729-40D1-92AD-5A5951B08030 Q35163327-0E2C9F88-5EEC-4EDF-BD04-07BDD8B2B1BF Q35188507-B46F97D2-9784-476F-AF01-FBD240D872D8 Q35775886-3ADA11B4-7DD5-40EB-A2F1-E20E79BC3256 Q36602569-B6FF2319-F012-4273-878C-7F7B862AE3A0 Q36700472-AF9B5A5C-1BC8-4309-8C62-DE6E0E4A8A4A Q36886874-3155D6EA-A467-4C96-A9CF-682C8EE662D8 Q37052095-9F7D837F-47D4-490E-B5C2-EE23FEC29649 Q37136114-50F30BA0-6ECC-4827-94C8-90251F356478 Q37228744-4273C12C-6164-4922-ACDA-74C99E99B594 Q37311285-397DDC83-32BD-43B2-9B34-A29C0E710C30 Q37643119-9EDBB0D1-FB8C-40A0-A94D-192E8B12C6C1 Q37715826-C106BEE1-5D03-46D3-AC90-E26405B8BB59 Q38172113-A56AD1F4-38A7-4F69-93C9-9F923EDCE48D Q38701929-EAA36025-F3C8-4455-8A8F-95E2B7E1EA08 Q38834030-FD801DC0-A6FD-45E1-80B1-127C0E888039 Q38880357-2D9CF642-87A5-4E34-B4D4-55799830437A Q38934509-34D0C08F-01AB-4374-B4ED-C5B6B0085510

P2860

Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations

http://www.wikidata.org/entity/Q36703641

description

1999 nî lūn-bûn

@nan

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

1999年论文

@zh

1999年论文

@zh-cn

name

Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations

@ast

Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations

@en

type

label

Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations

@ast

Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations

@en

prefLabel

Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations

@ast

Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations

@en

P1433

Q36703641-B3CD0308-41B2-4EC9-906A-A9E859667EF6

P1476

Q36703641-01B6B457-1CAA-4361-873A-E392C308863F

P2093

Q36703641-02DB905E-578D-4238-84B6-442EF0F91A0C

Q36703641-1AAC96BF-5FEA-4415-BAA6-AB1476937483

Q36703641-9AB7313F-CDE0-488D-B836-EDE6F791CC0B

Q36703641-B001F135-8A69-4088-A080-8A1E1B73EAE8

Q36703641-B3C83EA5-05C1-4E8D-ADB1-4B9A8EAB6E12

P2860

Q36703641-054A82AE-27F3-4C58-A84A-7651F2326EF1

Q36703641-16390AAE-9DB3-40B5-BDE8-7778C49ED5B0

Q36703641-1804BD05-2B0A-482F-985F-D82368563315

Q36703641-1C49EE4F-DCB9-4B01-B2DD-ADE227EA726F

Q36703641-217AEF84-73B3-43B3-A957-0836705F89B2

Q36703641-261BDFD4-657F-447C-ABDB-87D47D8CCF9D

Q36703641-2C26D458-3970-4B53-A611-738B66F992C4

Q36703641-4007F31F-E0E1-4F3D-AE1C-E1CDF14DE8A5

Q36703641-41BDB133-538C-4511-9629-920E0C8B3540

Q36703641-4B39F031-CC55-4DFA-AB0F-92B853C38F42

P304

Q36703641-D1D9F222-94A7-4BFE-819E-A8A2A7A1A58D

P31

Q36703641-37230BB4-6FD9-47D5-9424-E722170E9242

P356

Q36703641-0367184A-3EF6-4459-8F32-2F7AA5CA8584

P407

Q36703641-A61966A1-D7A2-4ECB-8307-6CB539D1457C

P433

Q36703641-8FF78CB6-52D5-484F-84EC-435B7440029C

P478

Q36703641-1958F9CC-CDCE-4247-A44A-E65B3C4BB380

P577

Q36703641-C6C5EA52-9666-4F84-8E0D-99983EE4C3B1

P5875

Q36703641-4CF47499-27A2-4277-9766-F59C58FEB252

P698

Q36703641-3B0DE327-27D6-454A-9343-D13878B077D2

P932

Q36703641-02EDE6C6-DE5F-484C-90C8-A84D02DC8616

P356

PNAS.96.24.13920

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations

@en

P2093

B H Spain

http://www.w3.org/2001/XMLSchema#string

C J Larson

http://www.w3.org/2001/XMLSchema#string

F H Gage

http://www.w3.org/2001/XMLSchema#string

I M Verma

http://www.w3.org/2001/XMLSchema#string

L S Shihabuddin

http://www.w3.org/2001/XMLSchema#string

P2860

Stable interaction between the products of the BRCA1 and BRCA2 tumor suppressor genes in mitotic and meiotic cells

Molecular cloning and expression of a receptor for human tumor necrosis factor

The BRC repeats in BRCA2 are critical for RAD51 binding and resistance to methyl methanesulfonate treatment

Cloning of an SNF2/SWI2-related protein that binds specifically to the SPH motifs of the SV40 enhancer and to the HIV-1 promoter

The BRCA2 gene product functionally interacts with p53 and RAD51

Compilation and analysis of sequences upstream from the translational start site in eukaryotic mRNAs

Cancer-susceptibility genes. Gatekeepers and caretakers

Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2

RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene brca2

BRCA1 is a 220-kDa nuclear phosphoprotein that is expressed and phosphorylated in a cell cycle-dependent manner

P304

13920-13925

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.96.24.13920

http://www.w3.org/2001/XMLSchema#string

P407

P433

24

http://www.w3.org/2001/XMLSchema#string

P478

96

http://www.w3.org/2001/XMLSchema#string

P577

1999-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12731414

http://www.w3.org/2001/XMLSchema#string

P698

10570174

http://www.w3.org/2001/XMLSchema#string

P932

24166

http://www.w3.org/2001/XMLSchema#string